Navigation Links
Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
Date:9/9/2008

BRIDGEWATER, N.J., Sept. 9 /PRNewswire-FirstCall/ -- Alpharma Inc. (NYSE: ALO), a global specialty pharmaceutical company, today announced results from its Phase III pivotal efficacy trial that showed ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) capsules provided significant pain relief in patients with moderate to severe pain due to osteoarthritis of the hip or knee compared to placebo. Findings also showed that ALO-01 capsules were safe and well-tolerated. This study was presented in a poster session at the 19th Annual Clinical Meeting of the American Academy of Pain Management in Nashville.

ALO-01 is an investigational pharmacologic abuse-deterrent, extended-release opioid that Alpharma is developing for the treatment of moderate to severe chronic pain. Utilizing Alpharma's proprietary technology, ALO-01 capsules combine an extended-release opioid, morphine sulfate, with a sequestered core of naltrexone, an opioid antagonist. When ALO-01 capsules are taken as directed, the naltrexone passes through the body without clinically meaningful release or accumulation.

According to the study findings, patients who were taking ALO-01 capsules reported significantly more effective pain relief, as measured by mean change in the weekly Brief Pain Inventory (BPI) Average Pain Intensity Score from baseline to the 12-week endpoint of the study, compared to patients who were taking placebo. Additionally, 72.5 percent of patients reported taking ALO-01 experienced pain relief of at least 30 percent from baseline, compared to 57.8 percent patients given placebo.

"These results are very exciting as we believe they demonstrate that ALO-01 has the potential to bring clear clinical ben
'/>"/>

SOURCE Alpharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- According to the new research ... Reagent, Primer, Probe, Custom Oligos), End-User (Research, Pharmaceutical ... NGS, DNA, RNAi) - Global Forecast to 2019" ... is expected to reach $1,712.1 Million by 2019 ... CAGR of 9.8% from 2014 to 2019.. ...
(Date:8/29/2014)... YORK, Pa. , Aug. 29, 2014  Unilife ...  ASX: UNS) announced today that it intends to release ... and year ended June 30, 2014 after market trading ... Management has scheduled a conference call for 4:30 p.m. ... 10, 2014 at 6:30 a.m. AEST), to review the Company,s ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Multiple Sclerosis Drugs Market 2014-2018" report to their ... inflammatory medical condition that results in demyelination, axonal transection, ... an abnormal response by the immune system, which targets ... a potentially debilitating disease in which the damage of ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... Diagnostics (SIX: RO, ROG; OTCQX: RHHBY) announced today that ... for cardiac biomarker testing on the cobas ® ... labs with medium testing volumes. With a 9-minute duration, ... tests currently available on an integrated platform and enable ...
... and MYSTIC, Conn., Sept. 16 Amarin Corporation plc (Nasdaq: ... Financial Officer, is scheduled to present on Amarin,s behalf at ... 2010 at 12:30 pm. This conference will be held at ... Stewart, recently appointed as President and Chief Executive Officer, will ...
Cached Medicine Technology:Roche Diagnostics Introduces Full Line of 9-Minute STAT Assays for Cardiac Biomarker Testing on cobas 6000 Analyzer Series 2Roche Diagnostics Introduces Full Line of 9-Minute STAT Assays for Cardiac Biomarker Testing on cobas 6000 Analyzer Series 3Amarin to Present at UBS Life Sciences Conference 2
(Date:8/29/2014)... (PRWEB) August 29, 2014 As reported by ... Addicts' Recovery , an Ohio municipal court drug has come ... addiction. Fred Moses, who serves as the presiding judge in ... law makers to offer addicts a medicated treatment option that ... utilizes the drug known as Vivitrol, which blocks receptors in ...
(Date:8/29/2014)... According to new research presented in a Science Daily article ... Drug Misuse Among Young Adults (8/16), peer pressure should ... it comes to prescription drug abuse. Researchers from Purdue University ... problem which influences misuse of prescription drugs is access to ... to have fun with other using friends. Evidently there is ...
(Date:8/29/2014)... Dallas, Texas (PRWEB) August 30, 2014 ... Glass microfiber Industry, 2009-2019 is a professional and ... microfiber industry. The report firstly reviews the basic ... and manufacturing technology. The report then explores global ... their product specification, capacity, Production value, and market ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Healthpointe has ... will give patients the convenience of visiting with physicians ... doctors through telemedicine. , Healthpointe doctors are always available ... audio). If necessary, the doctor can even see the ... patient’s condition, he or she can prescribe medications that ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Healthpointe ... Chapman University Physical Therapy students via Clinical Rotations. ... University will be shadowing Healthpointe providers and specialists ... them to develop clinical experience and learn professional ... students will gain insight into several patient care ...
Breaking Medicine News(10 mins):Health News:Ohio Judge Pushes for Addiction Recovery Tool 2Health News:Ohio Judge Pushes for Addiction Recovery Tool 3Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 2Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Virtual Doctor’s Appointments Now Available at Healthpointe 2Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2
... Rational Prescribing," a web-based lesson developed by faculty at ... Product of the Year" recently among products developed by ... The designation was made at the national meeting ... funds comprehensive programs to strengthen physicians, training in geriatrics. ...
... DALLAS and JACKSONVILLE, Fla., Jan. 11 Pollster Frank Luntz ... health care issue that resonates on both sides of the ... Christopher Fey, founder of U.S. Preventive Medicine®. , In the ... Doocy said, "Lawmakers will have to work out the Senate ...
... , , , PHILADELPHIA, Jan. 11 Global integrated ... in a state-of-the-art inventory management system - incorporating real ... and the Penn Customer Portal. This system makes Penn ... in the U.S. or Europe to provide customers with ...
... who have both diabetes and prostate cancer have significantly ... diabetes who undergo the same procedure, according to research ... Epidemiology, Biomarkers & Prevention . Many studies have ... of developing prostate cancer -- at least in white ...
... Mattress Warehouse will ... 9 a.m. to 5 p.m. The mattress retailer will be presenting mattresses from its Simmons ... (PRWEB) January ... Saturday and Sunday, January 16-17, 2010, 9 a.m. to 5 p.m. The mid-Atlantic mattress retailer ...
... The Executive Council of the International Association of Machinists ... health care reform legislation that is funded by taxing the ... IAM members exchanged substantial wage increases for the best possible ... bizarre turn of events, their insurance premiums will be subject ...
Cached Medicine News:Health News:Web-based curriculum in rational prescribing wins geriatrics Educational Product of the Year Award 2Health News:Republicans and Democrats Agree on The Prevention Plan(R); Ad Scores with Frank Luntz Audience 2Health News:Penn Pharma Invests In World-Class Inventory Management System 2Health News:Race, obesity affect outcomes among diabetics following prostatectomy 2Health News:Mattress Warehouse to Present at the NBC-4 Health & Fitness Expo in Washington, DC 2Health News:Machinists Union Leaders Vote to Oppose Health Benefits Tax 2
... VS1 is an easy to ... provides reliable, accurate, automated measurements ... designed to make your job ... bright, color-coded LED readings, proven ...
... (OLEH), an interactive electronic textbook, provides ... OLEH brings clinical decision support information ... right on the patient monitor screen ... and contributing to error reduction ...
... monitoring for flexible care settings., ... combine portability and measurement flexibility to ... of intermediate care environmentsat the patients ... heritage in patient monitoring, IntelliVue has ...
... The IntelliVue MP90 is designed to ... the highest acuity care environments. Built on ... IntelliVue MP90 with dual independent displays has ... measurements menu; built-in clinical support tools such ...
Medicine Products: